摘要
目的探讨氨磷汀对恶性肿瘤化疗患者的肝脏保护作用。方法选取100例既往化疗出现药物性肝损害的恶性肿瘤患者,采用随机数字表法分为研究组与对照组,每组患者各50例,研究组在化疗前接受氨磷汀单药治疗,对照组自化疗开始进行7 d的异甘草酸镁治疗,两组患者均在化疗前1天、化疗第10天复查血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)、总胆红素(TBIL)指标检测肝功能情况。结果研究组肝功能损害发生12例(24.0%),对照组则为28例(56.0%),两组间差异有统计学意义(χ~2=10.667,P=0.001)。患者化疗后10 d研究组、对照组肝功能指标ALT、AST,差异有统计学意义(P=0.038,P=0.013),而化疗后两组ALP、TBIL差异无统计学意义(P=0.907,P=0.248)。结论化疗前使用氨磷汀,可在一定程度上降低药物性肝功能损害发生率,提高化疗安全性。
Objective To observe the protection of hepatic toxicity by amifostine in malignant tumor patients receiving chemotherapy. Methods 100 cases had history of drug-induced liver injury were randomly divided into experimental group and control group. There were 50 cases in each group. The experimental group received amifostine before chemotherapy,while the control group received 7 days magnesium isoglycyrrhizinate from the beginning of chemotherapy.All patients were examined before chemotherapy and 10 days after therapy,including liver function markers of ALT,AST,ALP and TBIL. Results The incidence of liver damage in experimental group and the control group were 12( 24. 0%) and 28( 56. 0%),respectively. The difference was statistically significant between the two groups( χ~2=10. 667,P = 0. 001). ALT,AST,ALP,TBIL were detected 10 days after chemotherapy. The experimental group' s ALT and AST are statistically lower than those in control group( P = 0. 038,P = 0. 013). But there was no significant difference btween experimental group and control group about ALP and TBIL( P = 0. 907,P = 0. 248). Conclusion Amifostine is effective in protecting the injury of hepatic function caused by chemotherapy.
引文
[1]翟兴菊.异甘草酸镁联合熊去氧胆酸对化疗药物所致肝损害的预防作用查晓芳[J].中国实用医刊,2016,43(21):39-41.
[2]杜水仙,芦琳琳,辛永宁,等.药物性肝损伤患者住院时间的影响因素分析[J].临床肝胆病杂志,2016,32(7):1368-1372.
[3]王永伟.氨磷汀联合三维适形放疗对头颈部恶性肿瘤放疗损伤的影响[J].中国实用医药,2017,12(3):30-32.
[4]姜敏,曾越灿,迟峰,等.氨磷汀联合吉西他滨与顺铂方案治疗晚期乳腺癌的临床研究[J].实用药物与临床,2016,19(6):683-687.
[5]HOFER M,FALK M,KOMRKOVD.Two new faces of amifostine:protector from DNA damage in normal cells and inhibitor of DNA repair in cancer cells[J].J Med Chem,2016,59(7):3003-3017.
[6]FENG M,SMITH D E,NORMOLLE D P,et al.A Phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy[J].Int J Radiat Oncol Biol Phys,2012,83(5):1441-1447.
[7]刘丽霞.氨磷汀对合并肝炎的恶性肿瘤化疗患者肝脏保护作用的探析[J].中国实用医药,2013,8(5):187-188.
[8]郭君宾,刘泰然,叶海虹,等.氨磷汀对血液恶性肿瘤合并病毒性肝炎患者化疗期间的保护作用[J].中国乡村医药,2016,23(20):23-24.
